Search results for "FDA update"
Glucose monitoring app, weight-loss device, medications approved
The FDA approved an app for continuous glucose monitoring, a weight-loss device, a combination diabetes pill, and a new indication for an eye medication in the past month.
https://diabetes.acponline.org/archives/2015/02/13/7.htm
13 Feb 2015
New weight loss device approved
A new balloon device (the ReShape Dual Balloon) was recently approved by the FDA to treat obesity without invasive surgery.
https://diabetes.acponline.org/archives/2015/08/14/6.htm
14 Aug 2015
Rosiglitazone REMS ends, new insulin approved
The FDA has determined that the Risk Evaluation and Mitigation Strategy is no longer necessary to ensure that the benefits of rosiglitazone-containing drugs outweigh their risks.
https://diabetes.acponline.org/archives/2016/01/08/6.htm
8 Jan 2016
New weight loss drug approved
Lorcaserin hydrochloride (Belviq) was recently approved by the FDA for chronic weight management in adults.
https://diabetes.acponline.org/archives/2012/09/14/10.htm
14 Sep 2012
New drugs approved for diabetes
The first generic version of pioglitazone hydrochloride (Actos) and a new indication for ranibizumab injection (Lucentis) were recently announced by the FDA.
https://diabetes.acponline.org/archives/2012/11/09/9.htm
9 Nov 2012
Glucose monitoring system approved specifically for critical care units
The FDA recently approved a new indication for the Nova StatStrip Glucose Hospital Meter System, extending its use to critically ill patients who have been hospitalized.
https://diabetes.acponline.org/archives/2014/11/14/7.htm
14 Nov 2014
Empagliflozin approved to treat type 2 diabetes
Empagliflozin (Jardiance), a sodium glucose co-transporter 2 inhibitor, was recently approved to treat type 2 diabetes in addition to diet and exercise, the FDA announced last week.
https://diabetes.acponline.org/archives/2014/08/08/5.htm
8 Aug 2014
Single and combo diabetes drugs approved
Alogliptin (Nesina) and two new combination drugs (alogliptin and metformin hydrochloride [Kazano] and alogliptin and pioglitazone [Oseni]) were approved by the FDA to improve blood glucose control in adults with type 2 diabetes, along with diet and exercise.
https://diabetes.acponline.org/archives/2013/05/10/12.htm
10 May 2013